Recommendation of the President – Keytruda (pembrolizumab)

On 5 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No.17/2025 on the appraisal of a drug Keytruda (pembrolizumab) in medical program B.6. “Treatment of lung cancer patients (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”

Publication in Public Information Bulletin (BIP) >>